

HÃ¥kon Reikvam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/210249/publications.pdf>

Version: 2024-02-01

117
papers

2,231
citations

186209

28
h-index

289141

40
g-index

119
all docs

119
docs citations

119
times ranked

2819
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombosis and thrombocytopenia after HPV vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 700-704.	1.9	29
2	Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. <i>Molecules</i> , 2022, 27, 735.	1.7	13
3	An Abrupt Transition to Digital Teaching—Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown. <i>Healthcare (Switzerland)</i> , 2022, 10, 170.	1.0	5
4	Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 706.	1.0	10
5	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. <i>Biomolecules</i> , 2022, 12, 492.	1.8	1
6	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. <i>Current Oncology</i> , 2022, 29, 2193-2198.	0.9	0
7	MicroRNA serum profiles and chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 5295-5306.	2.5	6
8	Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia. <i>Expert Review of Proteomics</i> , 2022, , .	1.3	0
9	Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review. <i>Frontiers in Medicine</i> , 2022, 9, 819465.	1.2	9
10	Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. <i>Cancers</i> , 2022, 14, 2910.	1.7	4
11	Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 5-8.	1.1	3
12	Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 151-155.	0.4	1
13	Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. <i>Case Reports in Critical Care</i> , 2021, 2021, 1-6.	0.2	1
14	Carbapenem-Resistant Enterobacteriaceae—Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies. <i>Antibiotics</i> , 2021, 10, 322.	1.5	2
15	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. <i>Cells</i> , 2021, 10, 833.	1.8	4
16	Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1834.	1.0	8
17	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. <i>Cancers</i> , 2021, 13, 2143.	1.7	6
18	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. <i>Cancers</i> , 2021, 13, 1870.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. <i>Pharmaceuticals</i> , 2021, 14, 423.	1.7	4
20	Hyperferritinemia—A Clinical Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 2008.	1.0	48
21	Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. <i>Clinics and Practice</i> , 2021, 11, 459-466.	0.6	0
22	HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis. <i>Genes</i> , 2021, 12, 1162.	1.0	5
23	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. <i>Journal of Personalized Medicine</i> , 2021, 11, 779.	1.1	11
24	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. <i>Hemato</i> , 2021, 2, 607-627.	0.2	3
25	Future perspective: metabolism as a therapeutic target in acute myeloid leukemia — from Warburg to precision medicine. <i>Current Medical Research and Opinion</i> , 2021, 37, 2107-2111.	0.9	1
26	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2098841.	0.2	0
27	Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 74.	1.0	4
28	Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. <i>Journal of Clinical Medicine</i> , 2021, 10, 5190.	1.0	21
29	FEBRILE NEUTROPENIA IN ACUTE LEUKEMIA. EPIDEMIOLOGY, ETIOLOGY, PATHOPHYSIOLOGY AND TREATMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020009.	0.5	41
30	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. <i>Cells</i> , 2020, 9, 1677.	1.8	12
31	Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2020, 1, 102-110.	0.3	0
32	Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 217.	0.4	10
33	Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy. <i>Case Reports in Anesthesiology</i> , 2020, 2020, 1-5.	0.2	1
34	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. <i>Cells</i> , 2020, 9, 1155.	1.8	25
35	Critical Upper Airway Obstruction as the First Symptom of Acute Myeloid Leukemia—An Anesthesiologic Reminder. <i>Clinics and Practice</i> , 2020, 10, 34-36.	0.6	2
36	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment. <i>Case Reports in Hematology</i> , 2020, 2020, 1-6.	0.3	1

#	ARTICLE	IF	CITATIONS
37	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2907.	1.8	158
38	A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. <i>Journal of International Medical Research</i> , 2020, 48, 030006052090366.	0.4	5
39	Precision medicine for TP53-mutated acute myeloid leukemia. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 263-274.	0.4	2
40	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. <i>Journal of Clinical Medicine</i> , 2019, 8, 970.	1.0	26
41	Mondor's disease after extensive training with Nordic walking. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz075.	0.2	0
42	Trisomy 8 in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 947-958.	1.0	27
43	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 20.	7.1	46
44	Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 411-420.	1.9	13
45	Severe Nephritis as Initial Sign of Waldenström's Macroglobulinemia. <i>Clinics and Practice</i> , 2019, 9, 127-132.	0.6	0
46	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 377-387.	1.9	30
47	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. <i>Cytotherapy</i> , 2018, 20, 740-754.	0.3	5
48	Successful eradication of leptomeningeal plasma cell disease. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy038.	0.2	2
49	Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.3	3
50	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. <i>Cancers</i> , 2018, 10, 332.	1.7	24
51	Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. <i>Vox Sanguinis</i> , 2018, 113, 657-668.	0.7	7
52	Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	6
53	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. <i>Frontiers in Medicine</i> , 2018, 5, 147.	1.2	42
54	The Possible Importance of β_3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 251.	1.8	38

#	ARTICLE	IF	CITATIONS
55	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 382.	1.8	20
56	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 639-653.	1.5	14
57	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 553-569.	1.3	26
58	Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 357-369.	1.5	22
59	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1053-1065.	2.5	32
60	Microcirculation and red cell transfusion in patients with sepsis. <i>Transfusion and Apheresis Science</i> , 2017, 56, 900-905.	0.5	11
61	Non-curative surgery for aortoenteric fistula. <i>Journal of Surgical Case Reports</i> , 2017, 2017, rjx153.	0.2	5
62	CDC25 Inhibition in Acute Myeloid Leukemia – A Study of Patient Heterogeneity and the Effects of Different Inhibitors. <i>Molecules</i> , 2017, 22, 446.	1.7	12
63	Altered Immune Activation and IL-23 Signaling in Response to <i>Candida albicans</i> in Autoimmune Polyendocrine Syndrome Type 1. <i>Frontiers in Immunology</i> , 2017, 8, 1074.	2.2	12
64	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells. <i>BMC Cancer</i> , 2017, 17, 630.	1.1	18
65	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. <i>Frontiers in Immunology</i> , 2017, 8, 1979.	2.2	15
66	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. <i>Frontiers in Immunology</i> , 2016, 7, 205.	2.2	26
67	Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1823.	1.8	27
68	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 373-387.	0.6	3
69	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. <i>Metabolomics</i> , 2016, 12, 12.	1.4	34
70	Myeloproliferative neoplasier og JAK2-mutasjonar. <i>Tidsskrift for Den Norske Laegeforening</i> , 2016, 136, 1889-1894.	0.2	0
71	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3995-3995.	0.6	1
72	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. <i>Disease Markers</i> , 2015, 2015, 1-13.	0.6	15

#	ARTICLE	IF	CITATIONS
73	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. <i>Oncotarget</i> , 2015, 6, 2794-2811.	0.8	13
74	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. <i>Stem Cell Research</i> , 2015, 15, 530-541.	0.3	51
75	The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers – a comparative study of serum versus plasma samples. <i>Journal of Immunological Methods</i> , 2015, 418, 19-28.	0.6	18
76	Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. <i>Thrombosis Research</i> , 2015, 136, 30-39.	0.8	36
77	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication. <i>Expert Review of Hematology</i> , 2015, 8, 299-313.	1.0	13
78	Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 12.	1.0	24
79	Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. <i>Expert Review of Hematology</i> , 2015, 8, 315-327.	1.0	9
80	Nutrition in Allogeneic Stem Cell Transplantation - Clinical Guidelines and Immunobiological Aspects. <i>Current Pharmaceutical Biotechnology</i> , 2015, 17, 92-104.	0.9	7
81	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. <i>Blood</i> , 2015, 126, 4931-4931.	0.6	0
82	Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	0.3	15
83	Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia – The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms. <i>Molecules</i> , 2014, 19, 18414-18447.	1.7	67
84	Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. <i>Transfusion and Apheresis Science</i> , 2014, 51, 97-102.	0.5	25
85	Antileukaemic effect of PI3K – TOR inhibitors in acute myeloid leukaemia – gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. <i>British Journal of Haematology</i> , 2014, 164, 200-211.	1.2	34
86	Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. <i>SpringerPlus</i> , 2014, 3, 571.	1.2	19
87	Identification of a subset of patients with acute myeloid leukemia characterized by long-term <i>in vitro</i> proliferation and altered cell cycle regulation of the leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1237-1251.	1.5	24
88	Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 757-777.	2.0	34
89	Heat shock protein 70 – the next chaperone to target in the treatment of human acute myelogenous leukemia?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 929-944.	1.5	6
90	Comparison of <i>in vitro</i> responses to fresh whole blood and reconstituted whole blood after collagen stimulation. <i>Blood Transfusion</i> , 2014, 12, 50-5.	0.3	10

#	ARTICLE	IF	CITATIONS
91	The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicineâ€”The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation. <i>Toxins</i> , 2013, 5, 336-362.	1.5	29
92	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 551-563.	1.9	28
93	Predicting effects of kinase inhibitor in therapy for myeloid malignancies â€” the challenges in capturing disease heterogeneity. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1365-1370.	1.9	9
94	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	0.8	10
95	Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. <i>Oncotarget</i> , 2013, 4, 830-843.	0.8	43
96	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. <i>Blood</i> , 2013, 122, 2625-2625.	0.6	1
97	Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	0.8	6
98	The angioregulatory cytokine network in human acute myeloid leukemia â€” from leukemogenesis via remission induction to stem cell transplantation. <i>European Cytokine Network</i> , 2012, 23, 140-153.	1.1	44
99	The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. <i>Platelets</i> , 2012, 23, 299-308.	1.1	13
100	The Pretransplantation Serum Cytokine Profile in Allogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 190-199.	2.0	33
101	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. <i>European Journal of Haematology</i> , 2012, 89, 478-490.	1.1	14
102	Targeting of polo-like kinases and their cross talk with Aurora kinases â€” possible therapeutic strategies in human acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 587-603.	1.9	23
103	Questionnaire-Related Deferrals in Regular Blood Donors in Norway. <i>Journal of Blood Transfusion</i> , 2012, 2012, 1-4.	3.3	6
104	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status â€” consequences and potentials for pharmacological intervention. <i>British Journal of Haematology</i> , 2012, 156, 468-480.	1.2	39
105	Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. <i>American Journal of Hematology</i> , 2012, 87, 368-376.	2.0	31
106	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. <i>European Cytokine Network</i> , 2011, 22, 52-62.	1.1	17
107	Untangling the intracellular signalling network in cancer â€” A strategy for data integration in acute myeloid leukaemia. <i>Journal of Proteomics</i> , 2011, 74, 269-281.	1.2	6
108	Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-23.	3.0	69

#	ARTICLE	IF	CITATIONS
109	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. <i>European Journal of Haematology</i> , 2010, 84, 239-251.	1.1	50
110	The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 149-172.	0.7	45
111	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 169-183.	1.9	36
112	The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. <i>Blood Transfusion</i> , 2010, 8, 186-92.	0.3	29
113	Targeted therapy in acute myeloid leukaemia: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 433-455.	1.9	34
114	Thrombelastography. <i>Transfusion and Apheresis Science</i> , 2009, 40, 119-123.	0.5	130
115	Nuclear Factor- κ B Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. <i>Critical Reviews in Oncogenesis</i> , 2009, 15, 1-41.	0.2	47
116	Lymphoplasmacytic variant of multiple myeloma. <i>EJHaem</i> , 0, , .	0.4	1
117	Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future. <i>Expert Review of Hematology</i> , 0, , .	1.0	0